ARR 18565
Latest Information Update: 21 Jan 2008
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 19 Jan 2000 Preclinical development for Neurological disorders (Prevention) in USA (Unknown route)